[
    [
        {
            "time": "2020-01-14",
            "original_text": "The Extreme Risks of Trading Your Own Retirement Assets",
            "features": {
                "keywords": [
                    "Extreme Risks",
                    "Trading",
                    "Retirement Assets"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "The Extreme Risks of Trading Your Own Retirement Assets",
                "Correlation": 1,
                "Sentiment": 3,
                "Importance": 2,
                "Impact": 1,
                "Duration": 2,
                "Entity_Density": 1,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-01-14",
            "original_text": "AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.",
            "features": {
                "keywords": [
                    "AbbVie Inc.",
                    "Moody's",
                    "ratings",
                    "review"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Inc. -- Moody's announces completion of a periodic review of ratings of AbbVie Inc.",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-01-14",
            "original_text": "New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks",
            "features": {
                "keywords": [
                    "SKYRIZI",
                    "risankizumab",
                    "Cosentyx",
                    "secukinumab",
                    "Phase 3 Data",
                    "Superior"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-01-14",
            "original_text": "AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary",
            "features": {
                "keywords": [
                    "AbbVie",
                    "MAVIRET",
                    "listed",
                    "formulary",
                    "Newfoundland",
                    "Labrador"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie's MAVIRET® now listed on the Newfoundland and Labrador formulary",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]